Franz Albert Hoffmann

Lenalidomide as salvage therapy after allo-SCT for multiple myeloma is effective and leads to an increase of activated NK (NKp44+) and T (HLA-DR+) cells

Michael Lioznov, Jean El Cheikh, Franz Albert Hoffmann et al. · Bone Marrow Transplantation · 2009 · 99 citations

Hematological Malignancy, Oncology, Health Sciences +11

Combined bendamustine, prednisolone and thalidomide for refractory or relapsed multiple myeloma after autologous stem‐cell transplantation or conventional chemotherapy: results of a Phase I clinical trial

Wolfram Pönisch, Marta Rozanski, Hartmut Goldschmidt et al. · British Journal of Haematology · 2008 · 82 citations · Full text

Cell Replacement Therapy, Pharmacotherapy, Autologous Stem‐cell Transplantation +17

Combined bendamustine, prednisone and bortezomib (BPV) in patients with relapsed or refractory multiple myeloma

Wolfram Pönisch, Malvina Bourgeois, Barbara Moll et al. · Journal of Cancer Research and Clinical Oncology · 2012 · 38 citations · Full text

Hematological Malignancy, Medicine, Hematology +6

Bendamustine and prednisone in combination with bortezomib (BPV) in the treatment of patients with relapsed or refractory multiple myeloma and light chain-induced renal failure

Wolfram Pönisch, Barbara Moll, Malvina Bourgeois et al. · Journal of Cancer Research and Clinical Oncology · 2013 · 38 citations · Full text

Hematological Malignancy, Oncology, Medicine +6

Lenalidomide, bendamustine and prednisolone exhibits a favourable safety and efficacy profile in relapsed or refractory multiple myeloma: final results of a phase 1 clinical trial <scp>OSHO</scp> – #077

Wolfram Pönisch, Simone Heyn, Juliane Beck et al. · British Journal of Haematology · 2013 · 32 citations · Full text